Clinical trial NCT05720377: Evaluation of Exercise Application Technology in Adolescents
Official title: Evaluation of Exercise Application Technology and Continuous Glucose Monitoring to Improve Weight Loss and Metabolic Markers in Adolescents
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Type 2 Diabetes
PreDiabetes
Obesity
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
First posted: 2023-02-09
Enrollment: 0
Sex: ALL
Minimum age (years): 14
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: longitudinal
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate the use of an exercise phone application and a continuous glucose monitor and their impact on metabolic disease in adolescents with obesity, prediabetes and Type 2 diabetes. Participants will be asked to wear a continuous glucose monitor (Freestyle Libre) and if they are in the intervention group also participate in using an exercise phone application as well as have scheduled interval contact with a health professional in between scheduled clinic visits to assess how they are reaching their goals.

Detailed description: Patients will be recruited directly from the Childrens of Alabama pediatric endocrine clinic. Thirty patients who have obesity, prediabetes or Type 2 diabetes will be enrolled. During the enrollment phase, flyers will be posted in clinic and emails will be distributed to potential participants. Our study team will approach interested participants during their routine clinic visit. Consent will be obtained by study team during their endocrine clinic visit. Review of their medical records will be done and age, gender and race will be extracted from the medical record. A baseline visit with vital signs, blood work, a physical exam and nutritional counseling will be completed. Once enrolled, the patients will then be randomized.Within this pilot trial, we will randomize 15 adolescents/teenagers who either have obesity, prediabetes or Type 2 diabetes, to access to an exercise regimen and 15 adolescents to control intervention using a permuted block randomization scheme. The randomization scheme will contain 6 blocks of size 5 allowing for 30 randomized in the group with obesity, prediabetes and Type 2 diabetes.

Those who are in the intervention group will then be given access to frequent telephone counseling to follow-up their nutrition and exercise goals, access to exercise application and accelerometer as described below. Follow-up will then be completed at 3 and 6 months with a physical exam, vital signs, blood draw.

Intervention Group

Access provided to exercise application Provided with Fitbit to wear and measure activity Weekly check-in with provider to determine how exercise goals have been that week. If unable to reach, we will text securely a clinic check-in and provide a healthy tip of the week.

Meeting with nutrition at Baseline visit

Continuous glucose monitor provided (plan to wear for 14 days during each month)

Non-Intervention Group

Meeting with nutrition at Baseline visit

Continuous glucose monitor provided (plan to wear for 14 days at baseline visit, 3 month visit and 6 month visit)

Eligibility criteria: Inclusion Criteria for Type 2 diabetes arm

* BMI \> 95th percentile
* A1c\> 6.5%
* Age 14-17 (2 years post-menarchal)

Inclusion for Prediabetes Arm

* Age 14-17 (2 years post-menarchal)
* A1c 5.7-6.4%

Inclusion for Obesity Arm

* Age 14-17 (2 years post-menarchal)
* A1c 5.7-6.4%

Exclusion Criteria for all arms

* BMI \<95th percentile
* Specific obesity syndrome
* Inability to participate in exercise workouts

Primary outcomes:
measure: skin fold thickness
timeFrame: baseline
measure: skin fold measurement
timeFrame: 3 month
measure: skin fold measurement
timeFrame: 6 month
measure: Body mass index
timeFrame: baseline
measure: Body mass index
timeFrame: 3 month
measure: Body Mass Index
timeFrame: 6 month
Secondary outcomes:
measure: TNF-alpha
timeFrame: baseline
measure: TNF-alpha
timeFrame: 3 months
measure: TNF-alpha
timeFrame: 6 months
measure: IL-6
timeFrame: Baseline
measure: IL-6
timeFrame: 3 months
measure: IL-6
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
References: